Anti-inflammatory activity of neutrophil elastase inhibitors

Current Opinion in Investigational Drugs

Volumn 4, Issue 5, 2003, Pages 556-565

  Tremblay, Guy M ^a,b   Janelle, Marie France ^a   Bourbonnais, Yves ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

1 Antitrypsin deficiency; Anti inflammatory agents; Cystic fibrosis; Inflammation; Leukocyte elastase; Serine protease inhibitors

Indexed keywords

AE 3763; ALPHA 1 ANTITRYPSIN; CE 1037; CP 955; DX 890; EPI HNE 4; FK 706; FR 136706; GW 311616; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; LEX 032; MACROGOL; MDL 101146; MIDESTEINE; MONOCYTE LEUKOCYTE ELASTASE INHIBITOR; N [1 (1,3 BENZODIOXOL 5 YL)BUTYL] 3,3 DIETHYL 2 [4 [(4 METHYL 1 PIPERAZINYL)CARBONYL]PHENOXY] 4 OXO 1 AZETIDINECARBOXAMIDE; N [4 [(4 CHLOROPHENYLSULFONYL)AMINOCARBONYL]BENZOYL]VALYLPROLYLVALYL TRIFLUOROMETHYL KETONE; ONO 6818; PLACEBO; PRE ELAFIN; PROTEIN INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SIVELESTAT; SSR 69071; SUPG 032; TEI 8362; UNCLASSIFIED DRUG; ZD 0892; ZD 8321;

ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPHYSEMA; ENZYME INHIBITION; HUMAN; INFLAMMATION; LIVER FUNCTION TEST; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TISSUE INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; LEUKOCYTE ELASTASE; SERPINS;

EID: 0037841814     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (178)

1. Lee WL, Downey GP: Leukocyte elastase: Physiological functions and role in acute lung injury. Am J Respir Crit Care Med (2001) 164(5):896-904. Comprehensive review on neutrophil elastase emphasizing its role in lung inflammation.
2. Shapiro SD: Neutrophil elastase: Path clearer, pathogen killer, or just pathologic? Am J Respir Cell Mol Biol (2002) 26(3):266-268.
3. Döring G: The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med (1994) 150(6 Pt 2):S114-S117.
4. Witko-Sarsat V, Descamps-Latscha B: Neutrophil-derived oxidants and proteinases as immunomodulatory mediators in inflammation. Mediators Inflamm (1994) 3:257-273.
5. Owen CA, Campbell EJ: The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol (1999) 65(2):137-150.
6. Shapiro SD: The pathogenesis of emphysema: The elastase:antielastase hypothesis 30 years later. Proc Assoc Am Physicians (1995) 107(3):346-352.
7. 1-Antitrypsin deficiency: Biological answers to clinical questions. Am J Med Sci (2001) 321(1):33-41.
8. Shapiro SD: Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans (2002) 30(2):98-102.
9. Balfour-Lynn IM: The protease-antiprotease battle in the cystic fibrosis lung. J R Soc Med (1999) 92(Suppl 37):23-30.
10. Suter PM: Elastase and its physiological inhibitors in ARDS: What decides between inflammatory storm or dead calm? Eur Respir J (1999) 13(5):947-948.
11. Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J: The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. Chest (1997) 112(5):1338-1343.
12. Nadel JA, Takeyama K, Agusti C: Role of neutrophil elastase in hypersecretion in asthma. Eur Respir J (1999) 13(1):190-196.
13. Skiles JW, Jeng AY: Therapeutic promises of leukocyte elastase and macrophage metalloelastase inhibitors for the treatment of pulmonary emphysema. Exp Opin Ther Pat (1999) 9(7):869-895.
14. Reid PT, Sallenave J-M: Neutrophil-derived elastases and their inhibitors: Potential role in the pathogenesis of lung disease. Curr Opin Invest Drugs (2001) 2(1):59-67.
15. Ohbayashi H: Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs (2002) 11(7):965-980.
16. Ohbayashi H: Current synthetic inhibitors of human neutrophil elastase. Exp Opin Ther Pat (2002) 12(1):65-84.
17. 1-Antitrypsin: Structure, function, physiology. In: Acute Phase Proteins. Molecular Biology, Biochemistry, and Clinical Applications. Mackiewicz A, Kushner I, Baumann H (Eds), CRC Press, Boca Raton, FL, USA (1993):149-167.
18. 1-antichymotrypsin and is stimulated by proteinases. J Exp Med (1988) 168(4):1293-1306.
19. Scuderi P, Dorr RT, Liddil JD, Finley PR, Meltzer P, Raitano AB, Rybski J: α-Globulins suppress human leukocyte tumor necrosis factor secretion. Eur J Immunol (1989) 19(5):939-942.
20. Stockley RA, Shaw J, Afford SC, Morrison HM, Burnett D: Effect of α-1-proteinase inhibitor on neutrophil chemotaxis. Am J Respir Cell Mol Biol (1990) 2(2):163-170.
21. 1-antitrypsin. FEBS Lett (1992) 300(1):21-24.
22. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW: Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J Exp Med (1993) 178(5):1629-1636.
23. 1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol (1996) 157(11):5126-5129.
24. 1-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation (2000) 102(12):1420-1426.
25. 1-antitrypsin. Am J Respir Cell Mol Biol (2000) 22(2):244-252.
26. Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, Martin R, MacKenzie R, Xie C, Zhang L, Shapiro S, Wright JL: α-1-Antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest (2001) 81(8):1119-1131.
27. 1-Antitrypsin inhibitor deficiency and cystic fibrosis. Pediatr Pulmonol (1999) 28(5):363-375.
28. Hutchinson DCS, Hughes MD: α-1-Antitrypsin replacement therapy: Will its efficacy ever be proved? Eur Respir J (1997) 10(10):2191-2193.
29. 1-antitrypsin deficiency: Is the jury still out on a trial? Thorax (1998) 53(12):1007-1009.
30. 1-antitrypsin deficiency. Pharmacology and clinical recommendations. Biodrugs (2000) 13(2):135-147.
31. 1-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med (2000) 162(6):2069-2072.
32. 1-protease inhibitor. Chest (2001) 119(3):737-744.
33. 1-Antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can Respir J (2001) 8(2):81-88.
34. 1-antitrypsin deficiency. Am J Respir Crit Care Med (2002) 165(11):1494-1498.
35. 1-Antitrypsin deficiency: A report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur Respir J (2002) 20(4):1050-1056.
36. Bayer Corp: Prolastin. Company World Wide Web Site (2002) March 24. http://www.bayerdirect.com/pro.htm/
37. 1-antitrypsin, Respitin. Chest (2002) 122(1):66-74.
38. Alpha Therapeutic Corp: Alpha Therapeutic Corporation receives FDA approval for Aralast α-1 proteinase inhibitor. Baxter to serve as exclusive, worldwide distributorw. Press Release (2003) January 09.
39. Aventis Behring LLC: Aventis Behring submits application for FDA approval of new intravenous α-1 antitrypsin to treat hereditary emphysema. Press Release (2003) January 06.
40. 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 337(8738):392-394.
41. Cantin AM, Woods DE: Aerosolized Prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med (1999) 160(4):1130-1135.
42. 1-protease inhibitor in cystic fibrosis. Electrophoresis (2001) 22(1):165-171
43. 1-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity. Pulm Pharmacol Ther (2001) 14(6):461-467.
44. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM: Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest (2002) 109(5):661-670. Study proposing that elastase contributes to chronic inflammation in cystic fibrosis by impairing clearance of dying apoptotic cells.
45. 1-antitrypsin (AAT), PPL therapeutics. Curr Opin Mol Ther (2000) 2(2):199-204.
46. 1-antitrypsin for hereditary emphysema patients. Press Release (2001) April 10.
47. Aventis Behring LLC: Aventis Behring to initiate multinational pivotal trial for novel inhaleable therapy for hereditary emphysema. Press Release (2001) September 17.
48. Arriva Pharmaceuticals Inc: Hereditary emphysema. Company World Wide Web Site (2003) May 06. http://www.arrivapharm.com/clinical-respDiseases-emphy.php/
49. 1-antitrypsin.
50. Cantin AM, Woods DE, Cloutier D, Heroux J, Dufour EK, Leduc R: Leukocyte elastase inhibition therapy in cystic fibrosis: Role of glycosylation on the distribution of α-1-proteinase inhibitor in blood versus lung. J Aerosol Med (2002) 15(2):141-148.
51. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA (1986) 83(18):6692-6696.
52. Dijkman H: Antileucoprotease in the airways and emphysema. Monaldi Arch Chest Dis (1995) 50(5):383-387.
53. Tomee JFC, Koeter GH, Hiemstra PS, Kauffman HF: Secretory leukoprotease inhibitor: A native antimicrobial protein presenting a new therapeutic option? Thorax (1998) 53(2):S114-S116.
54. Shugars DC: Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis (1999) 179(Suppl 3):431-435.
55. 2, and matrix metalloproteinases. J Clin Invest (1997) 99(5):894-900.
56. Ding A, Zhu J, Jin F, Grobmyer SR, Nathan CF: Anti-inflammatory function of secretory leukocyte protease inhibitor. J Endotoxin Res (1999) 5(3):167-169.
57. Sano C, Shimizu T, Sato K, Kawauchi H, Tomioka H: Effects of secretory leucocyte protease inhibitor on the production of the anti-inflammatory cytokines, IL-10 and transforming growth factor-β (TGF-β), by lipopolysaccharide-stimulated macrophages. Clin Exp Immunol (2000) 121(1):77-85.
58. Lentsch AB, Jordan A, Czermak BJ, Diehl KM, Younkin EM, Sarma V, Ward PA: Inhibition of NF-κB activation and augmentation of IκBβ by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol (1999) 154(1):239-247.
59. Zhu J, Nathan C, Ding A: Suppression of macrophage responses to bacterial lipopolysaccharide by a non-secretory form of secretory leukocyte protease inhibitor. Biochim Biophys Acta (1999) 1451(2-3):219-223.
60. Taggart CC, Greene CM, McElvaney NG, O'Neill S: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IκBα degradation without affecting phosphorylation or ubiquitination. J Biol Chem (2002) 277(37):33648-33653.
61. Gillissen A, Birrer P, McElvaney NG, Buhl R, Vogelmeir C, Hoyt RF Jr, Hubbard RC, Crystal RG: Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol (1993) 75(2):852-832.
62. Kikuchi T, Abe T, Yaekashiwa M, Tominaga Y, Mitsuhashi H, Satoh K, Nakamura T, Nukiwa T: Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts. Am J Respir Cell Mol Biol (2000) 23(3):364-370.
63. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, Sarma V, Gibbs DF, Tefera W, McConnell PC, Mueller WT et al: Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol (1999) 162(6):3653-3662.
64. Ding A, Thieblemont N, Zhu J, Jin F, Zhang J, Wright S: Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infect Immun (1999) 67(9):4485-4489.
65. Huber-Lang M, Younkin EM, Sarma JV, Riedemann N, McGuire SR, Lu KT, Kunkel R, Younger JG, Zetoune FS, Ward PA: Generation of C5a by phagocytic cells. Am J Pathol (2002) 161(5):1849-1859.
66. Vogelmeier C, Buhl R, Hoyt RF, Wilson E, Fells GA, Hubbard RC, Schnebli H-P, Thompson RC, Crystal RG: Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol (1990) 69(5):1843-1848.
67. Gast A, Anderson W, Probst A, Nick H, Thompson RC, Eisenberg SP, Schnebli H: Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Am Rev Respir Dis (1990) 141(4 Pt 1):889-894.
68. Bergenfeldt M, Björk P, Ohlsson K: The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest (1990) 50(7):729-737.
69. Birrer P, McElvaney NG, Gillessen A, Hoyt RF, Bloedow DC, Hubbard RC, Crystal RG. Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense. J Appl Physiol (1992) 73(1):317-323.
70. Lucey EC, Stone PJ, Ciccolella DE, Breuer R, Christensen TG, Thompson RC, Snider GL: Recombinant human secretory leukocyte-protease inhibitor: In vitro properties, and amelioration of human neutrophil elastase-induced emphysema and secretory cell metaplasia in the hamster. J Lab Clin Med (1990) 115(2):224-232.
71. 1-proteinase inhibitor: Effect on human neutrophil elastase-induced experimental emphysema and pulmonary localization. Histochem J (1994) 26(10):817-824.
72. Rudolphus A, Stolk J, Dijkman JH, Kramps JA: Inhibition of lipopolysaccharide-induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor. Am Rev Respir Dis (1993) 147(2):442-447.
73. Mulligan MS, Desrochers PE, Chinnaiyan AM, Gibbs DF, Varani J, Johnson KJ, Weiss SJ: In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci USA (1993) 90(24)11523-11527.
74. Mitsuhashi H, Asano S, Nonaka T, Masuda K, Kiyoki M: Potency of truncated secretory leukoprotease inhibitor assessed in acute lung injury models in hamsters. J Pharmacol Exp Ther (1997) 282(2):1005-1010.
75. Mitsuhashi H, Asano S, Nonaka T. Hamamura I, Masuda K, Kiyoki M: Administration of truncated secretory leukoprotease inhibitor ameliorates bleomycin-induced pulmonary fibrosis in hamsters. Am J Respir Crit Care Med (1996) 153(1):369-374.
76. Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ: Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology (1992) 117(4):953-961.
77. Simpson R, Alon R, Kobzik L, Valeri CR, Shepro D, Hechtman HB: Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion. Ann Surg (1993) 218(4):444-454.
78. Song X. Zeng L, Jin W, Thompson J, Mizel DE, Lei K, Billinghurst RC, Poole AR, Wahl SM: Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med (1999) 190(4):535-542.
79. Cavarra E, Lucatteli M, Gambelli F, Bartalesi B, Fineschi S, Szarka A, Giannerini F, Martorana PA, Lungarella G: Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. Am J Physiol (2001) 281(2):L412-L417.
80. Rudolphus A, Heinzel-Wieland R, Vincent VAMM, Saunders D, Steffens GJ, Dijkman JH, Kramps JA: Oxidation-resistant variants of recombinant antileucoprotease are better inhibitors of human-neutrophil-elastase-induced emphysema in hamsters than natural recombinant antileucoprotease. Clin Sci (1991) 81(6):777-784. Design and evaluation of an improved SLPI by substituting the oxidation-sensitive methionine of the active site by a leucine.
81. Stolk J, Heinzel-Wieland R, Saunders D, Dijkman JH, Steffens G: Potency of an oxidation-resistant mutant of secretory leukocyte proteinase inhibitor in lipopolysaccharide-induced emphysema in hamsters. Pulm Pharmacol (1993) 6(1):33-39.
82. Schuster A, Hansen G, Zubrod-Eichert C, Wahn V: Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic fibrosis sputum: Inhibition of neutrophil elastase activity and of sputum-induced secretion from porcine tracheal submucosal glands. Pediatr Res (1996) 40(5):732-737.
83. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, Baker JB, Catalano MA, Crystal RG: Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 90(4):1296-1301. Demonstration that aerosolized SLPI may break the vicious circle of inflammation in cystic fibrosis.
84. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG: Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis (1992) 148(4 Pt 1):1056-1060.
85. Stolk J, Camps J, Feitsma HI, Hermans J, Dijkman JH, Pauwels EK: Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax (1995) 50(6):645-650.
86. Schalkwijk J, De Roo C, De Jongh GJ: Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta (1991) 1096(2):148-154.
87. Molhuizen HOF, Alkemade HAC, Zeeuwen PLJM, De Jongh GJ, Wieringa B, Schalkwijk J: SKALP/elafin: An elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem (1993) 268(16):12028-12032.
88. Nara K, Ito S, Ito T, Suzuki Y, Ghoneim MA, Tachibana S, Hirose S: Elastase inhibitor elafin is a new type of a proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". J Biochem (1994) 115(3):441-448.
89. Molhuizen HOF, Schalkwijk J: Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol Chem Hoppe Seyler (1995) 376(1):1-7.
90. Schalkwijk J, Wiedow O, Hirose S: The trappin gene family: Proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J (1999) 340(Pt 3):569-577. Excellent review by experts in the field on a very unique family of proteins, including pre-elafin.
91. Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave J-M: Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett (1999) 452(2):309-313.
92. Pfundt R, Van Ruissen F, Van Vlijmen-Willems IMJJ, Alkemade HAC, Zeeuwen PLJM, Jap PH, Dijkman H, Fransen J, Croes H, Van Erp PEJ, Schalkwijk J: Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J Clin Invest (1996) 98(6):1389-1399.
93. Tremblay GM, Sallenave J-M, Israël-Assayag E, Cormier Y, Gauldie J: Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am J Respir Crit Care Med (1996) 154(4 Pt 1):1092-1098.
94. Bingle L. Tetley TD, Bingle CD: Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-κB. Am J Respir Cell Mol Biol (2001) 25(1):84-91.
95. Van De Kerkhof PCM, Kuppens LHCM, Van Vlijmen Y, Schalkwijk J: Distribution of skin-derived antileucoproteases (SKALP) in the marginal zone of the spreading psoriatic lesion. Br J Dermatol (1991) 124(1):10-12.
96. Alkemade JAC, Molhuizen HOF, Ponec M, Kempenaar JA, Zeeuwen PLJM,. De Jongh GJ, Van Vlijmen-Willems IMJJ, Van Erp PEJ, Van De Kerkhof PCM Schalkwijk J: SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci (1994) 107(Pt 8):2335-2342.
97. Cowan B, Baron O, Crack J, Coulber C, Wilson GJ, Rabinovitch M:Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation. J Clin Invest (1997) 97(11):2452-2468.
98. Zaidi SSHE, Hui C-C, Cheah AYL, You X-M, Husain M, Rabinovitch M: Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. J Clin Invest (1999) 103(8):1211-1219.
99. Zaidi SHE, You X-M, Ciura S, O'Blenes S, Husain M, Rabinovitch M: Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. J Clin Invest (2000) 105(12):1687-1695.
100. O'Blenes SB, Zaidi SHE, Cheah AYL, McIntyre B, Kaneda Y, Rabinovitch M: Gene transfer of the serine elastase inhibitor elafin protects against vein graft degeneration. Circulation (2000) 102(19 Suppl):III289-III295.
101. Barolet AW, Nili N, Cheema A, Robinson R, Natarajan MK, O'Blenes S, Li J, Eskandarian MR, Sparkes J, Rabinovitch M, Strauss BH: Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler Thromb Vasc Biol (2001) 21(8):1269-1274.
102. Zaidi SHE, You X-M., Ciura S, Husain M, Rabinovitch M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation (2002) 105(4):516-521.
103. Rabinovitch M: EVE and beyond, retro and prospective insights. Am J Physiol (1999) 277(1 Pt 1):L5-L12.
104. Bourbonnais Y, Larouche E, Tremblay GM: Production of full-length human pre-elafin, an elastase specific inhibitor, from yeast requires the absence of a functional yapsin 1 (Yps1p) endoprotease. Protein Expr Purif (2000) 20(3)485-491.
105. Tremblay GM, Vachon E, Larouche C, Bouronnais Y: Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). Chest (2002) 121(2):582-588.
106. Vachon E, Bourbonnais Y, Bingle CD, Rowe SJ, Janelle MF, Tremblay GM: Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol Chem (2002) 383(7-8):1249-1256.
107. Sohn J, Kim T-I, Yoon Y-H, Kim J.-Y, Kim S-Y: Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest (2003) 111(1):121-128. Original approach to engineer recombinant peptides with potent anti-inflammatory activities.
108. Remold-O'Donnell E, Chin J, Alberts M: Sequence and molecular characterization of human monocyte/neutrophil elastase inhibitor. Proc Natl Acad Sci USA (1992) 89(12):5635-5639.
109. Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O'Donnell E: The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry (2001) 40(51):15762-15770.
110. Cooley J, Mathieu B, Remold-O'Donnell E, Mandle RJ: Production of recombinant human monocyte/neutrophil elastase inhibitor (rM/NEI). Protein Expr Purif (1998) 14(1):38-44.
111. Rees DD, Rogers RA, Cooley J, Mandle RJ, Kenney DM, Remold-O'Donnell E: Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am J Respir Cell Mol Biol (1999) 20(1):69-78. Demonstration of the therapeutic potential of rM/NEI in neutrophil proteinase-driven inflammatory diseases including cystic fibrosis.
112. CBR Labs Inc: Pharmaceutical potential of rM/NEI. Company World Wide Web Site (2003) May 06. http://store.yahoo.com.cbrlabs/pharmaceutical.html
113. Sands H, Hook JB: Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: The first of a potential new class of drugs. Drug Metab Rev (1997) 29(1-2):309-328.
114. Sands H, Tuma RF: LEX 032: A novel recombinant human protein for the treatment of ischaemic reperfusion injury. Expert Opin Investig Drugs (1999) 8(11):1907-1916.
115. Groutas WC, Ruan S, Kuang R, Hook JB, Sands H: Inhibition of human leukocyte proteinase 3 by a novel recombinant serine proteinase inhibitor (LEX032). Biochem Biophys Res Commun (1997) 233(3):697-699.
116. Scalia R, Gauthier TW, Lefer AM: Beneficial effects of LEX032, a novel recombinant serine protease inhibitor, in murine traumatic shock. Shock (1995) 4(4):251-256.
117. Von Dobschuetz E, Hoffmann T, Messmer K: Inhibition of neutrophil proteinases by recombinant serpin LEX032 reduces capillary no-reflow in ischemia/reperfusion-induced acute pancreatitis. J Pharmacol Exp Ther (1999) 290(2):782-788.
118. Weaver M, Leshley K, Sands H, Gritman KR, Legos JJ, Tuma RF: LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia. Microvasc Res (2002) 63(3):327-334.
119. Murohara T, Guo J-P, Lefer AM: Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. J Pharmacol Exp Ther (1995) 274(3):1246-1253.
120. Delyani JA, Murohara T, Lefer AM: Novel recombinant serpin, LEX032, attenuates myocardial reperfusion injury in cats. Am J Physiol (1996) 270(3 Pt 2):H881-H887.
121. Carney DF, Jagels MA, Hugli TE, Sands H, Rubin H: Effect of serine proteinase inhibitors on neutrophil function: α-1-proteinase inhibitor, antichymotrypsin, and a recombinant hybrid mutant of antichymotrypsin (LEX032) modulate neutrophil adhesion interactions. J Leukoc Biol (1998) 63(1):75-82.
122. G-nitro-L-arginine methyl ester induced leukocyte-endothelial cell interactions. Eur J Pharmacol (1998) 356(1):67-72.
123. Dyax Corp: DX-890. Company World Wide Web Site (2003) May 06. http://www.dyax.com/print/p_dx890.asp
124. Debiopharm SA: Debio: Product pipeline. Company World Wide Web Site (2002) December 31. http:/www.debio.com/e/debiopharm/pipeline_e.aspx
125. Delacourt C, Hérigault S, Delclaux C, Poncin A, Levame M, Harf A, Saudubray F, Lafuma C: Protection against lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol (2002) 26(3):290-297. First demonstration of the therapeutic potential of an elastase inhibitor engineered from the second Kunitz-type domain of inter-α-inhibitor.
126. Metz WA, Peet NP: Inhibitors of human neutrophil elastase as a potential treatment for inflammatory diseases. Exp Opin Ther Pat (1999) 9(7):851-868.
127. Metz WA, Peet NP: Elastase inhibitors. In: High Throughput Screening for Novel Anti-inflammatories. Kahn M (Ed), Birkhäuser Verlag, Basel, Switzerland (2000):49-85.
128. Ilies MA, Supuran CT, Scozzafava A: Therapeutic applications of serine protease inhibitors. Exp Opin Ther Pat (2002) 12(8):1181-1214.
129. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T: ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun (1991) 177(2):814-820.
130. Yoshimura K, Nakagawa S, Koyama S, Kobayashi T, Homma T: Roles of neutrophil elastase and superoxide anion in leukotriene B4-induced lung injury in rabbit. J Appl Physiol (1994) 76(1):91-96.
131. Sakamaki F, Ishizaka A, Urano T, Sayama K, Nakamura H, Terashima T, Waki Y, Tasaka S, Hasegawa N, Sato K, Nakagawa N et al: Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med (1996) 153(1):391-397.
132. Nishina K, Mikawa K, Takao Y, Maekawa N, Shiga M, Obara H: ONO-5046, an elastase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth Analg (1997) 84(5):1097-1103.
133. Kawabata K, Hagio T, Matsumoto S, Nakao S, Orita S, Aze Y, Ohno H: Delayed neutrophil elastase inhibition prevents subsequent progression of acute lung injury induced by endotoxin inhalation in hamsters. Am J Respir Crit Care Med (2000) 161(6):2013-2018.
134. Yamamoto H, Koizumi T, Kaneki T, Hanaoka M, Kubo K: Effects of lecithinized superoxide dismutase and a neutrophil elastase inhibitor (ONO-5046) on hyperoxic lung injury in rat. Eur J Pharmacol (2000) 409(2):179-183.
135. Wang HG, Shibamoto T, Miyahara T, Haniu H, Tanaka S, Fujimoto K, Honda T, Kubo K, Koyama S: Effect of ONO-5046, a specific neutrophil elastase inhibitor, on the phorbol myristate acetate-induced injury in isolated dog lung. Exp Lung Res (1999) 25(1):55-67.
136. Hagio T, Nakao S, Matsuoka H, Matsumoto S, Kawabata K, Ohno H: Inhibition of neutrophil elastase activity attenuates complement-mediated lung injury in the hamster. Eur J Pharmacol (2001) 426(1-2):131-138.
137. Miyazaki Y, Inoue T, Kyi M, Sawada M, Miyake S, Yoshizawa Y: Effects of a neutrophil elastase inhibitor (ONO-5046) on acute pulmonary injury induced by tumor necrosis factor α (TNFα) and activated neutrophils in isolated perfused rabbit lungs. Am J Respir Crit Care Med (1998) 157(1):89-94.
138. Kushimoto S, Okajima K, Uchiba M, Murakami K, Harada N, Okabe H, Takatsuki K: Role of granulocyte elastase in ischemia/reperfusion injury of rat liver. Crit Care Med (1996) 24(11):1908-1912.
139. Yamaguchi Y, Akizuki E, Ichiguchi O, Matsumura F, Goto M, Miyanari N, Mori K, Yamada S, Ogawa M: Neutrophil elastase inhibitor reduces neutrophil chemoattractant production after ischemia-reperfusion in rat liver. Gastroenterology (1997) 112(2):551-560.
140. Suzuki S, Gejyo F, Kuroda T, Kazama JJ, Imai N, Kimura H, Arakawa M: Effects of a novel elastase inhibitor, ONO-5046, on nephrotoxic serum nephritis in rats. Kidney Int (1998) 53(5):1201-1208.
141. Shimakura A, Kamanaka Y, Ikeda Y, Kondo K, Suzuki Y, Umemura K: Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion. Brain Res (2000) 858(1):55-60.
142. Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H: Suppressive effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cell Immunol (1995) 165(1):26-32.
143. Tonai T, Shiba K-I, Taketani Y, Ohmoto Y, Murata K, Muraguchi M, Ohsaki H, Takeda E, Nishisho T: A neutrophil elastase inhibitor (ONO-5046) reduces neurologic damage after spinal cord injury in rats. J Neurochem (2001) 78(5):1064-1072.
144. Wang FS, Yamaguchi Y, Akizuki E, Miyanari N, Ichiguchi O, Goto M, Mori K, Yamada S, Ogawa M: Neutrophil elastase inhibitor (ONO-5046) decreases cytokine-induced neutrophil chemoattractant after reperfusion of pancreaticoduodenal transplantation in rats. Transplantation (1996) 61(7):1103-1107.
145. Haga Y, Ogawa M: Neutrophil elastase inhibitor (ONO-5046.Na) decreases production of proinflammatory cytokines by lipopolysaccharide-stimulated human monocytes. Res Commun Mol Pathol Pharmacol (1997) 98(3):243-248.
146. Kinoshita M, Ono S, Mochizuki H: Neutrophils mediate acute lung injury in rabbits: Role of neutrophil elastase. Eur Surg Res (2000) 32(6):337-346.
147. Takayama M, Ishibashi M, Ishii H, Kuraki T, Nishida T, Yoshida M: Effects of neutrophil elastase inhibitor (ONO-5046) on lung injury after intestinal ischemia-reperfusion. J Appl Physiol (2001) 91(4):1800-1807.
148. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I: Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukocyte Biol (2001) 69(2):241-247.
149. Zeiher BG, Matsuoka S, Kawabata K, Repine JE: Neutrophil elastase and acute lung injury: Prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics. Crit Care Med (2002) 30(5 Suppl):S281-S287.
150. Ono Pharmaceutical Co Ltd: Announcement of the launch of Elaspol 100 for injection, the world's first drug for acute lung injury. Press Release (2002) June 13.
151. Ono Pharmaceutical Co Ltd: Announcement of the suspension of overseas clinical study with Elaspol 100 for injection. Press Release (2002) September 09.
152. Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M et al: Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem (2000) 43(26):4927-4929.
153. Ohmoto K, Okuma M, Yamamoto T, Kijima H, Sekioka T, Kitagawa K, Yamamoto
154. Odagaki Y, Ohmoto K, Matsuoka S, Hamanaka N, Nakai H, Toda M, Katsuya Y: The crystal structure of the complex of non-peptidic inhibitor of human neutrophil elastase ONO-6818 and porcine pancreatic elastase. Bioorg Med Chem (2001) 9(3):647-651.
155. Terui T, Sano K, Okada M, Shirota H, Honda M, Ozawa M, Hirasawa N, Tamura G, Tagami H: Production and pharmacologic modulation of the granulocyte-associated allergic responses to ovalbumin in murine skin models induced by injecting ovalbumin-specific Th1 or Th2 cells. J Invest Dermatol (2001) 117(2):236-243.
156. Kuraki T, Ishibashi M, Takayama M, Shiraishi M, Yoshida M: A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Am J Respir Crit Care Med (2002) 166(4):496-500.
157. Trifilieff A: ONO-6818 (Cortech/Ono). Curr Opin Invest Drugs (2002) 3(8):1161-1164.
158. 1 antitrypsin deficiency. Press Release (2002) November 01.
159. Shinguh Y, Imai K, Yamazaki A, Inamura N, Shima I, Wakabayashi A, Higashi Y, Ono T: Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor. Eur J Pharmacol (1997) 337(1):63-71.
160. Koizumi F, Murakami M, Kageyama H, Katashima M, Terakawa M, Ohnishi A: Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK706. Clin Pharmacol Ther (1999) 66(5):501-508.
161. Ishii K-I, Ito Y, Katagiri H, Matsumoto Y, Kakita A, Majima M: Neutrophil elastase inhibitor attenuates lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock (2002) 18(2):163-168.
162. Numanami H, Koyama S, Sato E, Haniuda M, Nelson DK, Hoyt JC, Freels JL, Habib MP, Robbins RA: Serine protease inhibitors modulate chemotactic cytokine production by human lung fibroblasts in vitro. Am J Physiol (2003) 284(5):L882-L890.
163. Kinoshita T, Nakanishi I, Sato A, Tada T: True interaction mode of porcine pancreatic elastase with FR136706, a potent peptidyl inhibitor. Bioorg Med Chem Lett (2003) 13(1):21-24.
164. Luisetti M, Piccioni PD, Donnini M, Peona V, Pozzi E, Grassi C: Studies of MR 889, a new synthetic proteinase inhibitor. Biochem Biophys Res Commun (1989) 165(2):568-573.
165. Baici A, Pelloso R, Hörler D: The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochem Pharmacol (1990) 39(5):919-924.
166. Moretti M, Gorrini M, Donnetta AM, Baldini EV, Venturini R, Marchioni CF, Iadarola P, Luisetti M: Effects of MR889, a cyclic thiolic neutrophil elastase inhibitor, on rheologic properties of mucus. Life Sci (1994) 54(7):463-469.
167. Luisetti M, Sturani C, Sella D, Madonini E, Galavotti V, Bruno G, Peona V, Kucich U, Dagnino G, Rosenbloom J, Starcher B et al: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled clinical trial. Eur Respir J (1996) 9(7):1482-1486.
168. Kuromiya A, Okazaki H, Kubo T, Imano K, Takemura T, Tsuji J, Komiya M: AE-3763, a novel inhibitor of neutrophil elastase (2): Effects of AE-3763 on acute organ failure models. Jpn J Pharmacol (2001) 85(Suppl. 1):P559.
169. Omodani T, Inoue Y, Shiratake R, Honda S, Sato F, Imano K, Okazaki H, Kubo T, Kuromiya A, Takemura T, Komiya M et al: Novel peptidyl trifluoromethyl ketone inhibitor of human neutrophil elastase. 221st National Meeting of the American Chemical Society, San Diego, CA, USA (2001).
170. Okazaki H, Kuromiya A, Kubo T, Imano K, Takemura T, Tsuji J, Sato F, Komiya M: A novel neutrophil elastase inhibitor, AE-3763 for treatment of acute organ injury. Effects in animal models. XVIIth International Symposium on Medicinal Chemistry, Barcelona, Spain (2002).
171. Kubo T, Okazaki H, Kuromiya A, Imano K, Takemura T, Tsuji J, Komiya M: AE-3763, a novel inhibitor of neutrophil elastase (1): Biochemical and pharmacological properties of AE-3763. Jpn J Pharmacol (2001) 85(Suppl 1):P558.
172. Dainippon Pharmaceutical Con Ltd: Dainippon Pharmaceutical Co Ltd: Annual Report 2002. Annual Report (2002) March 31.
173. Kapui Z, Varga M, Urban-Szabó K, Mikus E, Szabó T, Szeredi J, Bátori S, Finance O, Arányi P: Biochemical and pharmacological characterization of 2-(9-(2-Piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-me thylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. J Pharmacol Exp Ther (2003) 305(2):451-459.
174. Bidouard J-P, Duval N, Kapui Z, Herbert J-M, O'Connor SE, Janiak P: SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur J Pharmacol (2003) 461(1):49-52.
175. Bank U, Ansorge S: More than destructive: Neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol (2001) 69(2):197-206.
176. Barnes PJ: New treatments for COPD. Nat Rev Drug Discov (2002) 1(6):437-446.
177. Belaaouaj A: Neutrophil elastase-mediated killing of bacteria: Lessons from targeted mutagenesis. Microbes Infect (2002) 4(12):1259-1264.
178. Dainippon Pharmaceutical Co Ltd (Sato F, Inoue Y, Omodani T, Shiratake R, Honda S, Komiya M, Takemura T): Heterocyclic compounds, intermediates thereof and elastase inhibitors. EP-01157998 (2001).